According to CNBC, Jim Cramer's Charitable Trust raised its price target on Cardinal Health to $300 from $265 after the company reported fiscal 2027 first-quarter revenue of $67.51 billion, up 4% year over year, and adjusted earnings per share of $3.26, up 28%. The Trust reiterated its hold-equivalent 2 rating. Cardinal raised its full-year adjusted EPS guidance to $12.80-$13.00 from $12.40-$12.60 and lifted its profit-growth outlook for Pharmaceutical and Specialty Solutions to 10%-12% from 8%-11%.